10-Q quarterly report · filed Nov 3, 2026

ZEVRA THERAPEUTICS, INC. (ZVRA) Q3 2026 10-Q Quarterly Report

Short answer

ZEVRA THERAPEUTICS, INC. (ZVRA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 44.9% year over year) with net income of $19M.

Q3 2026 key financials · XBRL

Revenue
$38M
+44.9% YoY · −4.8% QoQ
Net income
$19M
+3630.9% YoY · +119.5% QoQ
Operating margin
30.7%
EPS (diluted)
$0.29
+107.1% QoQ

Source: XBRL data from the ZEVRA THERAPEUTICS, INC. (ZVRA) Q3 2026 10-Q on SEC EDGAR. USD.

ZEVRA THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $37.8M, up $11.7M YoY, driven by MIPLYFFA product sales increasing $11.6M
  • Net income $19.2M vs $0.5M loss YoY, operating income $11.6M vs $4.1M
  • MIPLYFFA strongest product, $11.6M YoY sales increase; OLPRUVA revenue $0.2M and sales efforts scaled back
  • Cash, cash equivalents and investments $270.9M; nine-month operating cash flow $33.2M vs $(7.1)M
  • EMA CHMP negative opinion on arimoclomol, re-examination requested; continued celiprolol Phase 3 development and commercial spending

Risk Factors

  • No material changes to risk factors since the March 31, 2026 Form 10-Q
  • Carried-forward risks remain those disclosed in the December 31, 2025 Form 10-K
  • Latest risk-factor update filed May 6, 2026 with the SEC

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ZEVRA THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.